ASP 4070

Drug Profile

ASP 4070

Alternative Names: ASP-4070; CryJ2 -DNA-LAMP; CryJ2 DNA LAMP plasmid vaccine; CryJ2-DNA-lysosomal associated membrane protein plasmid; Japanese red cedar LAMP vaccine; Japanese red cedar pollen allergy immunotherapy - Immunomic; JRC LAMP vaccine; JRC LAMP vax vaccine; JRC-LAMP-vax; JRC2-LAMP-vax; Sugi allergy vaccine

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomic Therapeutics
  • Developer Astellas Pharma; Immunomic Therapeutics
  • Class DNA vaccines; Japanese cedar pollen allergy immunotherapies; Vaccines
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tree pollen hypersensitivity
  • No development reported Allergic rhinitis; Allergic rhinoconjunctivitis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Tree pollen hypersensitivity in Japan (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Allergic-rhinitis in USA (Intradermal, Injection)
  • 18 Apr 2017 Astellas Pharma plans a phase II trial for Tree-pollen hypersensitivity in Japan (NCT03101267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top